OSI Pharmaceuticals is a biotechnology company primarily focused on the discovery, development, and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes, and obesity.
420 Saw Mill River Road
New York, United States
|2013-02-27||EpiTherapeutics||Series A||$6.55M||Lundbeckfond Ventures, Merck Ventures, Novo A/S, and SEED Capital|
|2009-07-17||AVEO Oncology||Series E||$20M|
|2005-11-21||Eyetech Pharmaceuticals||Acq - P2P|